OA10261A - New paroxetine derivatives - Google Patents

New paroxetine derivatives Download PDF

Info

Publication number
OA10261A
OA10261A OA60773A OA60773A OA10261A OA 10261 A OA10261 A OA 10261A OA 60773 A OA60773 A OA 60773A OA 60773 A OA60773 A OA 60773A OA 10261 A OA10261 A OA 10261A
Authority
OA
OAPI
Prior art keywords
paroxetine hydrochloride
paroxetine
solvaté
anhydrate
propan
Prior art date
Application number
OA60773A
Other languages
English (en)
Inventor
Victor Witold Jacewicz
Neal Ward
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27267578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10261(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9502297.6A external-priority patent/GB9502297D0/en
Priority claimed from GBGB9503112.6A external-priority patent/GB9503112D0/en
Priority claimed from GBGB9509807.5A external-priority patent/GB9509807D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA10261A publication Critical patent/OA10261A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
OA60773A 1995-02-06 1996-02-06 New paroxetine derivatives OA10261A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9502297.6A GB9502297D0 (en) 1995-02-06 1995-02-06 Novel compound
GBGB9503112.6A GB9503112D0 (en) 1995-02-17 1995-02-17 Novel compound
GBGB9509807.5A GB9509807D0 (en) 1995-05-15 1995-05-15 Novel compounds

Publications (1)

Publication Number Publication Date
OA10261A true OA10261A (en) 1997-09-19

Family

ID=27267578

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60773A OA10261A (en) 1995-02-06 1996-02-06 New paroxetine derivatives

Country Status (47)

Country Link
EP (3) EP1378508A1 (fr)
JP (2) JP2915338B2 (fr)
KR (1) KR100289885B1 (fr)
CN (3) CN1090187C (fr)
AR (2) AR001982A1 (fr)
AT (1) AT407528B (fr)
AU (2) AU701518C (fr)
BE (1) BE1009112A3 (fr)
BG (1) BG62967B1 (fr)
BR (1) BR9600534A (fr)
CA (2) CA2211522C (fr)
CH (3) CH689804A5 (fr)
CZ (1) CZ297171B6 (fr)
DE (3) DE69621777T2 (fr)
DK (2) DK11996A (fr)
DZ (1) DZ1989A1 (fr)
ES (1) ES2114471B1 (fr)
FI (3) FI111544B (fr)
FR (1) FR2730232B1 (fr)
GR (1) GR1002466B (fr)
HK (1) HK59397A (fr)
HU (1) HUP9600255A1 (fr)
IE (1) IE80500B1 (fr)
IL (1) IL117035A (fr)
IT (1) IT1289532B1 (fr)
LU (1) LU88711A1 (fr)
LV (1) LV11618B (fr)
MA (1) MA23802A1 (fr)
MC (1) MC2411A1 (fr)
MX (1) MX9600484A (fr)
MY (1) MY132529A (fr)
NL (1) NL1002248C2 (fr)
NO (3) NO301009B1 (fr)
NZ (1) NZ280943A (fr)
OA (1) OA10261A (fr)
PL (1) PL189247B1 (fr)
PT (1) PT101827B (fr)
RO (1) RO112426B1 (fr)
RU (1) RU2125052C1 (fr)
SE (1) SE521084C2 (fr)
SG (1) SG43787A1 (fr)
SI (2) SI21923B (fr)
SK (1) SK283608B6 (fr)
TR (1) TR199600096A2 (fr)
TW (1) TW503238B (fr)
UA (1) UA49796C2 (fr)
WO (1) WO1996024595A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (fr) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Procédé pour la préparation de hydrochlorure cristallin de paroxetine
WO1998002556A2 (fr) * 1996-07-15 1998-01-22 Smithkline Beecham Plc Criblage et utilisation d'esterase pour dedoublement stereospecifique
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
SK283394B6 (sk) 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
EP0903345B1 (fr) * 1997-08-08 2000-10-04 Aventis Pharma Deutschland GmbH Forme cristalline de N-(4-trifluorométhylphényl)-5-méthylisoxazole-4-carboxamid
GB9726907D0 (en) * 1997-12-19 1998-02-18 Smithkline Beecham Plc Novel compounds
HUP0101215A3 (en) * 1998-03-16 2002-05-28 Smithkline Beecham Plc Chrystalline form of paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
AU2003200534B2 (en) * 1998-03-24 2004-12-02 Smithkline Beecham Plc Paroxetine compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
JP3796351B2 (ja) * 1998-04-13 2006-07-12 住友化学株式会社 パロキセチン塩酸塩無水和物の乾燥方法
GB9812941D0 (en) * 1998-06-16 1998-08-12 Smithkline Beecham Plc Method of treatment
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
CA2339857A1 (fr) * 1998-08-07 2000-02-17 Neal Ward Procede de preparation d'une forme anhydre non cristalline d'hydrochlorure de paroxetine
GB9824298D0 (en) * 1998-11-05 1998-12-30 Smithkline Beecham Plc Novel process
GB9826175D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826176D0 (en) * 1998-11-28 1999-01-20 Smithkline Beecham Plc Novel process
GB9826180D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
EP1408039A3 (fr) * 1998-11-30 2004-05-12 Smithkline Beecham Plc Solvates mixtes de propan-2-ol et de paroxetine
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
IT1308629B1 (it) * 1999-02-23 2002-01-09 Recordati Chem Pharm Processo per la produzione di paroxetina.
JP4854115B2 (ja) * 1999-03-12 2012-01-18 エイシカ ファーマシューティカルス リミテッド 無水パロキセチン用安定製剤形
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
GB9919001D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel process
GB9923445D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923446D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
GB9923439D0 (en) * 1999-10-04 1999-12-08 Smithkline Beecham Plc Novel process
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
WO2002022609A1 (fr) * 2000-09-14 2002-03-21 Asahi Glass Company, Limited Procede de production de sel de paroxetine sensiblement exempt de solvant organique
WO2003072104A1 (fr) * 2002-02-22 2003-09-04 Teva Pharmaceutical Industries Ltd. Preparation de paroxetine impliquant de nouveaux intermediaires
EP1828098A1 (fr) * 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd FORMES CRISTALLINES DE CINACALCET HCl ET LEURS PROCÉDÉS DE SYNTHÈSE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0223403B1 (fr) * 1985-10-25 1993-08-04 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
AU658155B2 (en) * 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9325644D0 (en) * 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation

Also Published As

Publication number Publication date
MX9600484A (es) 1997-01-31
KR100289885B1 (ko) 2001-05-15
CA2210023C (fr) 1999-02-09
LU88711A1 (fr) 1996-08-23
CN1636993A (zh) 2005-07-13
EP1378508A1 (fr) 2004-01-07
SI21923A (sl) 2006-06-30
CH689804A5 (de) 1999-11-30
TR199600096A2 (tr) 1996-08-21
MC2411A1 (fr) 1996-12-02
DE69621777D1 (de) 2002-07-18
FR2730232B1 (fr) 1997-08-01
IE960104A1 (en) 1996-08-07
CA2168829A1 (fr) 1996-08-07
CA2211522A1 (fr) 1996-08-07
LV11618A (lv) 1996-12-20
HUP9600255A1 (en) 1997-03-28
FI960519A0 (fi) 1996-02-05
EP1136490A1 (fr) 2001-09-26
CN1216055C (zh) 2005-08-24
NO20015070L (no) 1996-08-07
DE69631298D1 (de) 2004-02-12
KR960031409A (ko) 1996-09-17
CN1143643A (zh) 1997-02-26
DK200100223A (fr) 2001-02-12
HU9600255D0 (en) 1996-03-28
CA2168829C (fr) 1997-12-16
DE69631298T2 (de) 2004-11-18
ITMI960203A0 (fr) 1996-02-05
ITMI960203A1 (it) 1997-08-05
RU2125052C1 (ru) 1999-01-20
JPH11228571A (ja) 1999-08-24
EP1136490B1 (fr) 2004-01-07
NL1002248A1 (nl) 1996-08-06
LV11618B (en) 1997-04-20
RO112426B1 (ro) 1997-09-30
GR1002466B (el) 1996-11-06
JP2915338B2 (ja) 1999-07-05
SI21923B (sl) 2006-12-31
NO970939D0 (no) 1997-02-28
FI20030162L (fi) 2003-02-03
HK59397A (en) 1997-05-16
CZ297171B6 (cs) 2006-09-13
IT1289532B1 (it) 1998-10-15
IE80500B1 (en) 1998-08-12
FI111544B (fi) 2003-08-15
SE9600406D0 (sv) 1996-02-05
AT407528B (de) 2001-04-25
AU4332896A (en) 1996-08-15
NZ280943A (en) 1997-01-29
BG62967B1 (bg) 2000-12-29
NO960472D0 (no) 1996-02-05
ES2114471B1 (es) 1999-08-16
FI20030162A7 (fi) 2003-02-03
PL189247B1 (pl) 2005-07-29
IL117035A (en) 2000-02-29
CH689229A5 (de) 1998-12-31
CA2211522C (fr) 1999-12-07
SG43787A1 (en) 1997-11-14
WO1996024595A1 (fr) 1996-08-15
DE19603797A1 (de) 1996-08-14
EP0808314B1 (fr) 2002-06-12
ES2114471A1 (es) 1998-05-16
EP0808314A1 (fr) 1997-11-26
BG100333A (bg) 1996-08-30
CA2210022C (fr) 2005-09-13
BE1009112A3 (fr) 1996-11-05
NO301009B1 (no) 1997-09-01
CN1289496C (zh) 2006-12-13
NL1002248C2 (nl) 1996-09-11
CA2210023A1 (fr) 1996-08-07
TW503238B (en) 2002-09-21
PT101827B (pt) 1997-08-29
SI9600036B (sl) 2006-12-31
NO301009B3 (fr) 2003-01-06
IL117035A0 (en) 1996-09-12
ATA21096A (de) 2000-08-15
CH688353A5 (de) 1997-08-15
SE521084C2 (sv) 2003-09-30
UA49796C2 (uk) 2002-10-15
FI20030370A7 (fi) 2003-03-12
DE19603797C2 (de) 1998-11-12
NO311519B1 (no) 2001-12-03
FR2730232A1 (fr) 1996-08-09
NO20015070D0 (no) 2001-10-18
CN1310180A (zh) 2001-08-29
SK14396A3 (en) 1996-11-06
CN1090187C (zh) 2002-09-04
DK11996A (da) 1996-08-07
DZ1989A1 (fr) 2002-10-15
SI9600036A (en) 1996-10-31
PL312646A1 (en) 1996-08-19
MY132529A (en) 2007-10-31
FI20030370L (fi) 2003-03-12
MX198371B (fr) 2000-08-29
NO960472L (no) 1996-08-07
SK283608B6 (sk) 2003-10-07
CA2210022A1 (fr) 1996-08-07
DE69621777T2 (de) 2003-01-02
AU701518C (en) 2006-12-07
AR036856A2 (es) 2004-10-06
AU4786496A (en) 1996-08-27
AU701518B2 (en) 1999-01-28
JPH08245620A (ja) 1996-09-24
NO970939L (no) 1996-08-07
AR001982A1 (es) 1998-01-07
SE9600406L (sv) 1996-08-07
CZ32096A3 (en) 1996-08-14
PT101827A (pt) 1996-09-30
BR9600534A (pt) 1997-05-13
MA23802A1 (fr) 1996-10-01
FI960519L (fi) 1996-08-07

Similar Documents

Publication Publication Date Title
OA10261A (en) New paroxetine derivatives
US6133289A (en) Paroxetine hydrochloride form A or C
CY2015A (en) Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
CA2210023E (fr) Procede de preparation d'anhydrate d'hydrochlorure de paroxetine, forme a
AU740561B2 (en) Paroxetine hydrochloride anhydrate
CA2211521A1 (fr) Nouveaux composes de paroxetine hydrochlorine anhydrate
CA2168829E (fr) Formes a, b, c et d de chlorhydrate de paroxetine deshydrate
LT4100B (en) Paroxetine hydrochloride anhydrate and process for preparing thereof